Healthcare provider profile · identity verified

Stuart P Turner, MD

Family Practice · MADISON, WI · NPI 1871548321

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	353	128
Omeprazole	Omeprazole	217	82
Simvastatin	Simvastatin	177	65
Hydrochlorothiazide	Hydrochlorothiazide	165	63
Lisinopril	Lisinopril	165	59
Amlodipine Besylate	Amlodipine Besylate	155	58
Metoprolol Tartrate	Metoprolol Tartrate	133	49
Furosemide	Furosemide	114	43
Levothyroxine Sodium	Levothyroxine Sodium	106	32
Metformin Hcl Er	Metformin Hcl	103	32
Metoprolol Succinate	Metoprolol Succinate	102	33
Tamsulosin Hcl	Tamsulosin Hcl	95	43
Pantoprazole Sodium	Pantoprazole Sodium	91	28
Losartan Potassium	Losartan Potassium	81	33
Gabapentin	Gabapentin	80	35
Metformin Hcl	Metformin Hcl	76	34
Warfarin Sodium	Warfarin Sodium	62	22
Allopurinol	Allopurinol	58	29
Eliquis	Apixaban	58	14
Trazodone Hcl	Trazodone Hcl	55	13
Rosuvastatin Calcium	Rosuvastatin Calcium	50	19
Clopidogrel	Clopidogrel Bisulfate	46	16
Duloxetine Hcl	Duloxetine Hcl	46	12
Fluticasone Propionate	Fluticasone Propionate	46	25
Glipizide	Glipizide	44	19
Quetiapine Fumarate	Quetiapine Fumarate	43	suppressed
Potassium Chloride	Potassium Chloride	40	15
Albuterol Sulfate Hfa	Albuterol Sulfate	39	20
Famotidine	Famotidine	38	17
Fluoxetine Hcl	Fluoxetine Hcl	38	suppressed
Atenolol	Atenolol	34	suppressed
Finasteride	Finasteride	34	13
Xarelto	Rivaroxaban	34	suppressed
Citalopram Hbr	Citalopram Hydrobromide	30	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	30	20
Montelukast Sodium	Montelukast Sodium	30	suppressed
Jardiance	Empagliflozin	29	suppressed
Topiramate	Topiramate	29	suppressed
Januvia	Sitagliptin Phosphate	28	suppressed
Carvedilol	Carvedilol	27	16
Doxazosin Mesylate	Doxazosin Mesylate	27	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	27	suppressed
Bupropion Xl	Bupropion Hcl	26	suppressed
Diclofenac Sodium	Diclofenac Sodium	26	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	25	suppressed
Pravastatin Sodium	Pravastatin Sodium	25	suppressed
Alendronate Sodium	Alendronate Sodium	24	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	24	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	24	suppressed
Enalapril Maleate	Enalapril Maleate	22	suppressed
Lovastatin	Lovastatin	22	suppressed
Ozempic	Semaglutide	22	suppressed
Tramadol Hcl	Tramadol Hcl	22	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	22	15
Acyclovir	Acyclovir	19	suppressed
Trulicity	Dulaglutide	19	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	18	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Prednisone	Prednisone	17	suppressed
Ibuprofen	Ibuprofen	16	suppressed
Lorazepam	Lorazepam	16	suppressed
Mirtazapine	Mirtazapine	16	suppressed
Sertraline Hcl	Sertraline Hcl	16	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Benazepril Hcl	Benazepril Hcl	14	suppressed
Colestipol Hcl	Colestipol Hcl	14	suppressed
Gemfibrozil	Gemfibrozil	14	suppressed
Labetalol Hcl	Labetalol Hcl	14	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Amoxicillin	Amoxicillin	13	suppressed
Celecoxib	Celecoxib	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Primidone	Primidone	13	suppressed
Clobetasol Propionate	Clobetasol Propionate	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Alprazolam	Alprazolam	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error